For patients 12 years of age and older with warm autoimmune hemolytic anemia (wAIHA) currently or previously treated with corticosteroids

NOW APPROVED!

IMAAVY® (nipocalimab-aahu) is the first and only FDA-approved treatment for patients 12 years and older with wAIHA currently or previously treated with corticosteroids.

Why choose IMAAVY?

IMAAVY
is the first & only FDA-approved treatment for

For adults and children 12 years and older with wAIHA currently or previously treated with corticosteroids

IMAAVY
was proven to increase

levels in a 24-week clinical study

24% of patients receiving IMAAVY compared with 8% of patients receiving

had improved hemoglobin levels* without the need for additional treatment^†

Individual results may vary. Talk to your healthcare provider to see if IMAAVY is right for you.

IMAAVY
is dosed once every
4 weeks

Received through an

^‡

IMAAVY
has a proven safety profile

The most common side effects reported in people with wAIHA taking IMAAVY were swelling in the hands, ankles, or feet; diarrhea; and fever

FDA=Food and Drug Administration.

*Improved hemoglobin levels were defined as hemoglobin levels ≥10 g/dL and an increase of ≥2 g/dL from the start of the study, without the need for additional treatment. These goals had to be met ≥3 times in a row over ≥28 days, starting by Week 16 of the clinical study. In this study, 38 patients received IMAAVY every 4 weeks, and 39 patients received placebo.

†No additional treatment means no rescue treatment (extra treatment) was given by a healthcare provider based on
worsening signs and symptoms of wAIHA.

^‡An IV infusion is given by a healthcare provider through a needle placed into your vein.

NOW APPROVED!

Get personalized support tailored to your unique needs

Learn more now

Get personalized support tailored
to your unique needs